• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Endocrinology

Abiraterone associated with improved survival for advanced prostate cancer: The STAMPEDE trial

byDavid ArsaniousandDayton McMillan
July 27, 2017
in Endocrinology, Oncology, Urology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Men treated with abiraterone, prednisolone, and androgen-deprivation therapy (ADT) (combined therapy) demonstrated a significantly increased overall survival in comparison to those treated with ADT alone.

2. Men treated with combined therapy demonstrated a significantly increased treatment failure-free survival in comparison to those treated with ADT alone.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: The standard of care for newly diagnosed locally advanced or metastatic prostate cancer involves long-term androgen deprivation therapy (ADT) in the form orchiectomy, gonadotropin releasing hormone (GnRH) antagonists, or GnRH agonists. Abiraterone has previously been demonstrated to improve survival in ADT relapsed prostate cancer, and so this study was performed to investigate the role of this CYP17 inhibitor in newly diagnosed locally-advanced or metastatic prostate cancer.

The overall survival rate was observed to be significantly improved in combined therapy versus the ADT-alone group. This trend was also seen for treatment failure-free survival, as treatment-failure events were significantly fewer in the combined therapy group. Regarding adverse events, 47% of patients randomized to combined therapy experienced a grade 3-5 adverse event, while this was seen in 33% of patients randomized to ADT alone.

This study’s greatest impact is in demonstrating a role for abiraterone in the treatment of newly diagnosed, advanced prostate cancer. That strength stems from the study’s large patient recruitment and fairly lengthy follow-up. Nonetheless, a limitation to this study can be identified in the absence of an as-treated analysis for patients treated with radiotherapy, despite the study’s reporting of the proportions of each group in which radiotherapy was planned.

Click to read the study, published today in NEJM

RELATED REPORTS

Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

#VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

Relevant Reading: Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial

In-Depth [randomized controlled trial]: The Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial was a multiarm, multistage, prospective, randomized, controlled trial in which 1917 patients were randomized in a 1:1 ratio to receive ADT alone (n = 957) or combined therapy (n = 960) with 1000 mg abiraterone and 5 mg prednisolone, both once daily. Eligible patients had prostate cancer that was either newly diagnosed and metastatic, node-positive, or high-risk locally advanced, or relapsing disease with high risk features. The primary outcome was overall survival, defined as the time from randomization to death from any cause. Stratification of patients was performed with attention to age, treatment center, presence of metastasis, and planned use of radiotherapy. The intermediate primary outcome was failure-free survival. The median follow-up was 40 months. There were 184 deaths in the combined therapy group as compared with 262 in the ADT group (HR, 0.63; 95% CI, 0.52-0.76; p < 0.001). There were 248 treatment failures in the combined therapy group, compared to 535 treatment failures in the ADT-alone group (HR, 0.29; 95% CI, 0.25-0.34; p < 0.001). Grade 3-5 adverse events were reported in 443 of 948 (47%) in the combination group and 315 of 960 (33%) in the ADT-alone group.

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: prostate cancer
Previous Post

2 Minute Medicine Rewind July 24, 2017

Next Post

Tocilizumab improves remission rates in giant-cell arteritis: The GiACTA trial

RelatedReports

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy

May 24, 2022
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

May 11, 2022
#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis
StudyGraphics

#VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

April 13, 2022
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Darolutamide improves overall survival in patients with hormone-sensitive prostate cancer

March 28, 2022
Next Post
Treatment of subclinical hypothyroidism ineffective in older adults

Tocilizumab improves remission rates in giant-cell arteritis: The GiACTA trial

Epileptogenic foci may be lateralized using functional brain glutamate imaging

Increased neurodegenerative pathology associated with chronic traumatic encephalopathy severity

African American and Hispanic youth more likely to discontinue ADHD treatment

Reduction in vaccination rates predicted to increase incidence and cost of measles

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
  • OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.